Weekly Analysts’ Ratings Updates for Vor Biopharma (VOR)

Vor Biopharma (NYSE: VOR) recently received a number of ratings updates from brokerages and research firms:

• 3/21/2025 – Vor Biopharma had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $8.00 price target on the stock.
• 3/21/2025 – Vor Biopharma had its price target lowered by analysts at HC Wainwright from $17.50 to $13.00. They now have a “buy” rating on the stock.
• 3/21/2025 – Vor Biopharma had its price target lowered by analysts at Stifel Nicolaus from $12.00 to $5.00. They now have a “buy” rating on the stock.
• 3/20/2025 – Vor Biopharma had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.

Vor Biopharma Stock Performance

Shares of NYSE VOR traded down $0.03 during trading on Monday, hitting $0.72. The company had a trading volume of 69,997 shares, compared to its average volume of 588,702. The stock has a 50 day simple moving average of $1.16 and a 200 day simple moving average of $1.01. The firm has a market capitalization of $89.89 million, a P/E ratio of -0.44 and a beta of -0.40. Vor Biopharma Inc. has a 12 month low of $0.63 and a 12 month high of $2.43.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of VOR. RA Capital Management L.P. grew its position in shares of Vor Biopharma by 74.3% during the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock worth $44,007,000 after purchasing an additional 16,897,159 shares in the last quarter. Lynx1 Capital Management LP purchased a new stake in Vor Biopharma during the 4th quarter valued at approximately $707,000. Two Sigma Investments LP raised its position in shares of Vor Biopharma by 18.9% during the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock valued at $181,000 after buying an additional 25,930 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock worth $175,000 after buying an additional 44,252 shares in the last quarter. Finally, Trustees of Columbia University in the City of New York bought a new position in shares of Vor Biopharma during the fourth quarter worth $102,000. 97.29% of the stock is owned by institutional investors.

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.